C-reactive protein, interleukin 6, and N-terminal pro-brain natriuretic peptide following cardioversion of atrial fibrillation: Is there a role of biomarkers in arrhythmia recurrence?

Angiology

Volumn 62, Issue 4, 2011, Pages 310-316

  Psychari, Stavroula N ^a,c   Chatzopoulos, Dionyssios ^a   Iliodromitis, Efstathios K ^b   Apostolou, Thomas S ^a   Kremastinos, Dimitrios T ^b  

^a Nikea General Hospital Athens   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c NONE   (Greece)

Author keywords

atrial fibrillation; C reactive protein; inflammation; natriuretic peptides

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 6;

ADULT; ARTICLE; CARDIOVERSION; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HEART LEFT ATRIUM VOLUME; HEART VOLUME; HOLTER MONITORING; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECURRENCE RISK; RECURRENT DISEASE; RELIABILITY; TRANSTHORACIC ECHOCARDIOGRAPHY;

ANALYSIS OF VARIANCE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; ECHOCARDIOGRAPHY; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; RECURRENCE;

EID: 79953867042     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319710382418     Document Type: Article

References (32)

1. Li H., Riedel R., Oldmeyer JB, Rovang K., Hee T. Comparison of recurrence rates after direct-current cardioversion for new-onset atrial fibrillation in patients receiving versus those not receiving rhythm-control drug therapy. Am J Cardiol. 2004 ; 93 (1). 45-48. (Pubitemid 38022031)
2. Van Noord T., Tieleman RG, Bosker HA, et al. Beta-blockers prevent subacute recurrences of persistent atrial fibrillation only in patients with hypertension. Europace. 2004 ; 6 (4). 343-350. (Pubitemid 38937149)
3. Singh NB, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007 ; 357: 987-999. (Pubitemid 47367078)
4. Engelmann MDM, Svendsen HJ Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J. 2005 ; 26 (20). 2083-2092. (Pubitemid 41408600)
5. Chung MK, Martin DO, Sprecher D., et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001 ; 104 (24). 2886-2891. (Pubitemid 33139098)
6. Aviles RJ, Martin DO, Apperson-Hansen C., et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003 ; 108 (24). 3006-3010. (Pubitemid 37553570)
7. Psychari SN, Apostolou TS, Sinos L., Hamodraka E., Liakos G., Kremastinos DT Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol. 2005 ; 95 (6). 764-767. (Pubitemid 40340139)
8. Casaclang-Verzosa G., Gersh BL, Tsang TS Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol. 2008 ; 51 (1). 1-11.
9. Ellinor PT, Low AF, Patton KK, Shea MA, MacRae CA Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation. J Am Coll Cardiol. 2005 ; 45 (1). 82-86. (Pubitemid 40052031)
10. Buob A., Jung J., Siaplaouras S., Neuberger HR, Mewis C. Discordant regulation of CRP and NT-proBNP plasma levels after electrical cardioversion of persistent atrial fibrillation. Pacing Clin Electrophysiol. 2006 ; 29 (6). 559-563. (Pubitemid 43886605)
11. Fuster V., Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006 ; 48: 854-906. (Pubitemid 44175743)
12. Lang RM, Bierig M., Devereux RB, et al. Recommendations for chamber quantification: a report of the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005 ; 18 (12). 1440-1463. (Pubitemid 41821197)
13. Goetze JP, Friis-Hansen L., Rehfeld JF, Nilsson B., Svendsen JH Atrial secretion of B-type natriuretic peptide. Eur Heart J. 2006 ; 27 (14). 1648-1650. (Pubitemid 44025348)
14. Levin ER, Gardner DG, Samson WK Natriuretic peptides. N Engl J Med. 1998 ; 339 (5). 321-328. (Pubitemid 28366422)
15. Kundsen CW, Omland T., Clopton P., et al. Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multinational study. J Am Coll Cardiol. 2005 ; 46 (5). 838-844. (Pubitemid 41224808)
16. Inoue SI, Murakami Y., Sano K., Katoh H., Shimada T. Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail. 2000 ; 6 (2). 92-96. (Pubitemid 30439442)
17. Wozakowska-Kaplon B. Effect of sinus rhythm restoration on plasma brain natriuretic peptide in patients with atrial fibrillation. Am J Cardiol. 2004 ; 93 (12). 1555-1558. (Pubitemid 38749221)
18. Date T., Yamane T., Inada K., et al. Plasma brain natriuretic peptide concentrations in patients undergoing pulmonary vein isolation. Heart. 2006 ; 92 (11). 1623-1627. (Pubitemid 44629169)
19. Wazni OM, Martin DO, Marrouche NF, et al. Plasma B-type natriuretic peptide levels predict postoperative atrial fibrillation in patients undergoing cardiac surgery. Circulation. 2004 ; 110 (2). 124-127. (Pubitemid 38924579)
20. Watanabe E., Arakawa T., Uchiyama T., Kodama I., Hishida H. High- sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after cardioversion. Int J Cardiol. 2006 ; 108 (3). 346-353. (Pubitemid 43339801)
21. Dernellis J., Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J. 2004 ; 25 (13). 1100-1107. (Pubitemid 38842447)
22. Conway DS, Buggins P., Hughes E., Lip GY Predictive value of indexes of inflammation and hypercoagulability on success of cardioversion of persistent atrial fibrillation. Am J Cardiol. 2004 ; 94 (4). 508-510. (Pubitemid 39120007)
23. Malouf JE, Kanagala R., Al Atawi FO, et al. High sensitivity C-reactive protein. A novel predictor for recurrence of atrial fibrillation after successful cardioversion. J Am Coll Cardiol. 2005 ; 46 (7). 1284-1287. (Pubitemid 41615550)
24. Leftheriotis DI, Fountoulaki KT, Flevari PG, et al. The predictive value of inflammatory and oxidative markers following the successful cardioversion of persistent lone atrial fibrillation. Int J Cardiol. 2009 ; 135 (3). 361-369.
25. Wazni O., Martin DO, Marrouche NF, et al. C-reactive protein concentration and recurrence of atrial fibrillation after electrical cardioversion. Heart. 2005 ; 91 (10). 1303-1305. (Pubitemid 41360947)
26. Loricchio ML, Cianfrocca C., Pascheri V., et al. Relation of C-reactive protein to long- term risk of recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol. 2007 ; 99 (10). 1421-1424. (Pubitemid 46691310)
27. Van Gelder IC, Crijns HJ, Van Gilst WH, Verwer R., Lie KI Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct- current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol. 1991 ; 68 (1). 41-46.
28. Tveit A., Seljeflot I., Grundvolt I., Abdelnoor M., Smith P., Arnesen H. Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. Am J Cardiol. 2007 ; 99 (11). 1544-1548. (Pubitemid 46770639)
29. Letsas KP, Weber R., Bürke G., et al. Pre-ablative predictors of atrial fibrillation recurrence following pulmonary vein isolation: the potential role of inflammation. Europace. 2009 ; 11 (2). 158-163.
30. Kourliouros A., Camm AJ Does inflammation influence atrial fibrillation recurrence following catheter ablation? Europace. 2009 ; 11 (2). 135-137.
31. Ma KK, Ogawa T., de Bold AJ Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by the pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol. 2004 ; 36 (4). 505-513. (Pubitemid 38469941)
32. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002 ; 347 (32). 1825-1833. (Pubitemid 35417773)